| August 2008
College Hill Appointed by ValiRx and NextGen Sciences
for Integrated Financial Communications Programmes
London, August 2008 College
Hill’s Life Sciences team has been appointed by ValiRx (AIM: VAL), London, UK, to
develop and implement an integrated financial and corporate communications programme
to raise its profile as a leader in the field of cancer therapeutics and diagnostics.
Sue Charles, Managing Partner, Life Sciences and Adrian
Duffield, Partner, TMT and Life Sciences will lead the account for ValiRx, supported
by Justine Lamond, Account Manager, and Dr John McIntyre.
ValiRx is a biopharmaceutical company that delivers novel
technologies and products in oncology therapeutics and diagnostics. Although primarily
focused on epigenomic analysis and the treatment of cancer, its technologies can
also be applied across fields such as neurology and inflammatory diseases. ValiRx
is headquartered in London, UK, and operates through two divisions: ValiPharma,
focused on cancer therapeutics; and ValiBio, focused on cancer diagnostics. www.valirx.com
Commenting on the wins, Sue Charles, Managing Partner
Life Sciences said: "We are extremely pleased to have been chosen to support ValiRx
with its financial communications programme. The win further extends our portfolio
of listed clients in the life science field".
For further information:
Sue Charles, Managing Partner – Life Sciences, College Hill
+44 (0)20 7457 2020
sue.charles[at]collegehill.com
|